<DOC>
	<DOCNO>NCT02212197</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics , pharmacodynamics , efficacy safety CAM2032 versus Eligard , patient prostate cancer . All patient receive leuprolide acetate administer subcutaneously monthly 3 month .</brief_summary>
	<brief_title>Phase II Study Subcutaneous Injection Depot Leuprolide Acetate Patient With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Men ≥40 ≤85 year age Histological cytological proven adenocarcinoma prostate require hormone therapy Life expectancy 12 month World Health Organisation/ The Eastern Cooperative Oncology Group ( WHO/ECOG ) performance status 0 , 1 2 Adequate stable renal function Adequate stable hepatic function Evidence brain metastasis , spinal cord compression , urinary tract obstruction Serum Testosterone level 150 ng/dL Screening visit Medical radiological prostate cancer treatment within 2 month prior Screening visit Surgical treatment prostate cancer within 2 week prior Screening visit Prior orchiectomy , hypophysectomy , adrenalectomy Prior use LHRH agonist within 12 month prior Screening visit study</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>leuprolide</keyword>
</DOC>